suma/breast neoplasms

The present invention relates to a pharmaceutical composition comprising a somatostatin analogue, and to its use in the treatment of breast cancer. Somatostatin is a tetradecapeptide incorporating a cyclic dodecapeptide having the structure: ##STR1## and has the properties of inhibiting the release

The present invention relates to a pharmaceutical composition comprising a somatostatin analogue, and to its use in the treatment of breast cancer. Somatostatin is a tetradecapeptide incorporating a cyclic dodecapeptide having the structure: ##STR1## and has the properties of inhibiting the release

GOVERNMENT INTERESTS Not applicable PARTIES TO A JOINT RESEARCH AGREEMENT Not Applicable INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC Not Applicable BACKGROUND Not Applicable BRIEF SUMMARY OF THE INVENTION Embodiments of the present invention are directed to methods for

FIELD OF THE INVENTION The present invention relates to adenine nucleotide translocator 2 (ANT2) siRNA (small interfering RNA) or ANT2 shRNA (short hairpin RNA) suppressing the expression of ANT2 gene expression and anticancer agent containing the same. Furthermore, the present invention relates to

FIELD OF THE INVENTION The present invention provides a method of identifying and/or isolating stem cells. The present invention also provides methods of using cell populations enriched for stem cells. In addition, the present invention provides methods for diagnosing and/or prognosing human acute

FIELD OF THE INVENTION The present invention provides a method of identifying and/or isolating stem cells. The present invention also provides methods of using cell populations enriched for stem cells. In addition, the present invention provides methods for diagnosing and/or prognosing human acute

FIELD OF INVENTION The present invention relates to a diagnostic marker for breast cancer, comprising thioredoxin-1 as an active ingredient, and a diagnostic kit for breast cancer using the same. The present invention further relates to a method for the diagnosis of breast cancer by measuring

FIELD OF THE INVENTION The present invention relates generally to methods and compositions for the detection and/or treatment of breast cancer. More specifically, the present invention relates to breast cancer-associated proteins and nucleic acids encoding such proteins which represent cellular

FIELD OF THE INVENTION The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of

FIELD OF THE INVENTION The present invention concerns the treatment of cancers characterized by the overexpression of of a tumor antigen, such as an ErbB receptor, particularly HER2. More specifically, the invention concerns more effective treatment of human patients susceptible to or diagnosed with

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 16, 2012, is named P11625-02_ST25.txt and

FIELD OF THE INVENTION The field of the present invention relates to disease diagnosis and treatment of cancer and identification of anti-cancer agents. BACKGROUND OF THE INVENTION Mitotic checkpoint genes have become widely studied for their roles in development as well as for their potential role

FIELD OF THE INVENTION The field of the present invention relates to disease diagnosis and treatment of cancer and identification of anti-cancer agents. BACKGROUND OF THE INVENTION Mitotic checkpoint genes have become widely studied for their roles in development as well as for their potential role

FIELD OF THE INVENTION The field of the present invention relates to disease diagnosis and treatment of cancer and identification of anti-cancer agents. BACKGROUND OF THE INVENTION Mitotic checkpoint genes have become widely studied for their roles in development as well as for their potential role

BACKGROUND This application relates generally to the field of treatment of breast cancer and more particularly to a predictive test for determining, in advance of treatment, whether a breast cancer patient is a member of a class of patients that would be likely to benefit from a combination of